01—Abstract
Summary
Summary of the 8-K filed July 23, 2024. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (NYSE: DHR) reported second quarter 2024 results for the quarter ended June 28, 2024, with revenue of $5.7 billiona, down 3.0% year-over-year (GAAP), and non-GAAP core revenue down 3.5%.
GAAP net earnings were $907 millionb, or $1.22 per diluted share, versus $1.24 in the prior-year quarter from continuing operations. Non-GAAP adjusted diluted EPS was $1.72, compared with $1.73 a year earlier, a roughly flat result. Operating cash flow was $1.4 billion and non-GAAP free cash flow from continuing operations was $1.1 billion, down about 14.5% year-over-year, largely reflecting lower operating cash generation and higher capital spending relative to the prior year period.
The quarter's segment picture was mixed. Biotechnology core sales fell 7.0%c and Life Sciences core sales fell 5.5%, while Diagnostics grew 3.0%, supported by Cepheid, which management believes gained molecular testing share. Management highlighted sustained positive momentum in bioprocessing.
Management reiterated its outlook for non-GAAP core revenue to decline at a low-single-digit rate in both the third quarter and full year 2024, which signals no near-term recovery in the top line. Investors will likely focus on whether the bioprocessing recovery and Diagnostics strength can offset weakness in Life Sciences and Biotechnology. The filing also shows a large financing outflow of $5.7 billiond in the quarter, which is well above the operating cash flow for the period.
Because the filing does not explain this outflow, investors should review the Form 10-Q for details on debt repayment or other financing activity. Net earnings were pressured by higher amortization of acquisition-related intangibles ($402 million pretax in the quarter), and interest income declined year-over-year, from $59 million to $39 million.
02—Key points
Key Highlights
- Revenue of $5.743 billion declined 3.0% year-over-year on a GAAP basis, and non-GAAP core revenue declined 3.5%, with acquisitions contributing a 2.0-point headwind and currency a 1.5-point tailwind.
- GAAP diluted EPS from continuing operations was $1.22 versus $1.24 a year earlier; non-GAAP adjusted diluted EPS was $1.72 versus $1.73, nearly flat.
- Segment core sales: Biotechnology down 7.0%, Life Sciences down 5.5%, and Diagnostics up 3.0%, with Cepheid cited as gaining molecular testing share.
- Free cash flow from continuing operations was $1.131 billion, down roughly 14.5% year-over-year, with operating cash flow of $1.417 billion, down about 14%.
- Guidance unchanged: non-GAAP core revenue expected to decline low-single digits in Q3 2024 and for full year 2024.
- Financing cash outflow of $5.715 billion in the quarter is not explained in the release and warrants review of the Form 10-Q.
- Pretax amortization of acquisition-related intangibles rose to $402 million from $372 million, and interest income fell to $39 million from $59 million.
03—Questions
Frequently Asked Questions
Did Danaher meet expectations and what drove the quarter?
The release does not state consensus estimates, so the comparison must rest on the company's own figures. Adjusted diluted EPS of $1.72 and free cash flow of $1.1 billion were reported as better than management expected, according to CEO Rainer Blair. Revenue declined 3.0%, and the quarter's stronger points were bioprocessing momentum and Cepheid's molecular testing performance.
Is Danaher's top-line outlook improving?
Not in the near term. Management continues to guide to non-GAAP core revenue declining at a low-single-digit rate in both Q3 2024 and full year 2024, which is unchanged from prior guidance. This suggests the company does not expect a meaningful reacceleration of growth in the second half of 2024.
Why did free cash flow decline and should investors be concerned?
Operating cash flow fell about 14% to $1.417 billion, and capital expenditures were $287 million versus $329 million a year earlier, so the FCF decline came from weaker operating cash generation. Free cash flow still covered a substantial portion of the company's needs, but the decline is worth monitoring along with the working capital and timing factors described in the 10-Q.
What is the $5.7 billion financing outflow?
The release reports net cash used in financing activities from continuing operations of $5.715 billion for the quarter, compared with $208 million a year earlier, but does not explain it. Investors should check the Form 10-Q for the breakdown, which may include debt repayment, share repurchases, or a related balance sheet action.
Why do GAAP and adjusted EPS differ so much?
The gap is mainly amortization of acquisition-related intangible assets, which was $0.54 per share in the quarter, plus fair value losses on investments of $0.08 per share. These are partly offset by a tax effect of $0.11. Management argues that excluding amortization aids comparability between acquired and long-held businesses, but the amortization is a real, recurring cost of past acquisitions until those intangibles are fully amortized.
04—Continue